Guggenheim Maintains Buy on Genmab, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Positive 74.1%

Neg 0% Neu 0% Pos 74.1%

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $42.